Comparing CxBladder to Urine Cytology as Adjunct to Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer—A Pilot Study

Chai, Chu Ann; Yeoh, Wei Sien; Rajandram, Retnagowri; Aung, K P; Ong, Teng Aik; Kuppusamy, Shanggar; Nazran, A; Kumaran, K; Razack, Azad Hassan Abdul; Teoh, Jeremy Yuen‐Chun

doi:10.3389/fsurg.2021.659292

Cited by 8 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A pilot study [ 46 ] compared CxBladder (Cxb) ( Table 4 ) achieved by reverse RT-qPCR urine cytology as an adjunct to surveillance cystoscopy (CS) after resection of NMIBC.…”

Section: What Is New In the Last Two Years?mentioning

confidence: 99%

A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers

Matuszczak

Kiljańczyk

Salagierski

2022

IJMS

View full text Add to dashboard Cite

The non-muscle invasive bladder cancer tends to recur and progress. Therefore, it requires frequent follow-ups, generating costs and making it one of the most expensive neoplasms. Considering the expensive and invasive character of the current gold-standard diagnostic procedure, white-light cystoscopy, efforts to find an alternative method are ongoing. Although the last decade has seen significant advancements in urinary biomarker tests (UBTs) for bladder cancer, international guidelines have not recommended them. Currently, the paramount urgency is to find and validate the test with the best specificity and sensitivity, which would allow for the optimizing of diagnosis, prognosis, and a treatment plan. This review aims to summarise the up-to-date state of knowledge relating to UBTs and new developments in the detection, prognosis, and surveillance of bladder cancer and their potential applications in clinical practice.

show abstract

“…A pilot study [ 46 ] compared CxBladder (Cxb) ( Table 4 ) achieved by reverse RT-qPCR urine cytology as an adjunct to surveillance cystoscopy (CS) after resection of NMIBC.…”

Section: What Is New In the Last Two Years?mentioning

confidence: 99%

A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers

Matuszczak

Kiljańczyk

Salagierski

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Cxbladder Resolve (CxbR) was developed for use after both CxbT and CxbD tests, to accurately segregate test-positive patients likely to have high-impact tumors. The test could detect BC in cases with atypical cytology and hematuria [ 206 , 225 , 226 , 227 , 228 ].…”

Section: Ease Of Developing Urine Biomarkersmentioning

confidence: 99%

Molecular Oncology of Bladder Cancer from Inception to Modern Perspective

Lokeshwar

López

Sarcan

et al. 2022

Cancers

View full text Add to dashboard Cite

Within the last forty years, seminal contributions have been made in the areas of bladder cancer (BC) biology, driver genes, molecular profiling, biomarkers, and therapeutic targets for improving personalized patient care. This overview includes seminal discoveries and advances in the molecular oncology of BC. Starting with the concept of divergent molecular pathways for the development of low- and high-grade bladder tumors, field cancerization versus clonality of bladder tumors, cancer driver genes/mutations, genetic polymorphisms, and bacillus Calmette-Guérin (BCG) as an early form of immunotherapy are some of the conceptual contributions towards improving patient care. Although beginning with a promise of predicting prognosis and individualizing treatments, “-omic” approaches and molecular subtypes have revealed the importance of BC stem cells, lineage plasticity, and intra-tumor heterogeneity as the next frontiers for realizing individualized patient care. Along with urine as the optimal non-invasive liquid biopsy, BC is at the forefront of the biomarker field. If the goal is to reduce the number of cystoscopies but not to replace them for monitoring recurrence and asymptomatic microscopic hematuria, a BC marker may reach clinical acceptance. As advances in the molecular oncology of BC continue, the next twenty-five years should significantly advance personalized care for BC patients.

show abstract

“…Ten studies evaluated the test metrics of an RNAbased urine assay in patients under surveillance for NMIBC [20,[25][26][27][28][29][30][31][32][33]]. An overview of articles is shown in Table 3.…”

Section: Surveillance Setting Of Non-muscle Invasive Bladder Cancermentioning

confidence: 99%

RNA-based urinary assays for non-muscle invasive bladder cancer

Pijpers

Jong

Zuiverloon

et al. 2022

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of reviewTo provide an overview of the recent literature on RNA-based molecular urine assays for the diagnosis and surveillance of non-muscle invasive bladder cancer (NMIBC).Recent findingsArticles were eligible for inclusion if performance metrics sensitivity, specificity, and negative-predictive value (NPV) were reported or could be calculated. Only prospective studies published between 2020–2022 were included. Five out of fourteen studies addressed the primary diagnostic setting; the proportion of gross hematuria patients in all study populations was >50%. Only one study reported performance metrics within a microscopic hematuria subgroup. This study evaluated Xpert Bladder and reported a sensitivity: 73%, specificity: 84%, NPV: 99%, and PPV: 12%. Ten studies assessed test performance during surveillance for NMIBC. For the detection of high-grade (HG) and high-risk (HR) NMIBC, sensitivity, specificity, NPV, and PPV varied between 78–100%, 64–89%, 97.0–99.7%, and 9.2–39%.SummaryMultiple RNA-based urine assays have been investigated for the detection of urothelial cancer in the primary or surveillance setting. However, studies included within this review have important limitations, hampering the interpretation of study results. As such, performance metrics should be interpreted with caution and further research is required to evaluate the clinical impact of RNA-based urine assays in daily practice.

show abstract

Comparing CxBladder to Urine Cytology as Adjunct to Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer—A Pilot Study

Cited by 8 publications

References 17 publications

A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers

A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers

Molecular Oncology of Bladder Cancer from Inception to Modern Perspective

RNA-based urinary assays for non-muscle invasive bladder cancer

Contact Info

Product

Resources

About